The Medical Letter on Drugs and Therapeutics
H1N1 Vaccine for Prevention of Pandemic Influenza
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has licensed 4 new monovalent vaccines for prevention of respiratory illness caused by a new influenza A H1N1 virus that appears to be derived from a swine strain. The 5th vaccine should be licensed soon. All of these vaccines are expected to become available in October. An intranasal formulation is expected in the first week of October.

THE DISEASE — The signs and symptoms of this H1N1 infection have been similar to those of the usual seasonal disease, except that diarrhea and vomiting have been more common and most hospitalizations have been in persons <65 years old.1

SUSCEPTIBILITY — Serologic evidence suggests that the majority of the population less than 60 years old is susceptible to infection with this H1N1 strain.2 Trivalent seasonal vaccination is unlikely to provide protection.3

FORMULATIONS ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: H1N1 Vaccine for Prevention of Pandemic Influenza
Article code: 1322a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian